Skip to search formSkip to main contentSkip to account menu

ML3000

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2008
2008
In Vitro Metabolism of 2-[6-(4-Chlorophenyl)-2,2-dimethyl-7-phenyl-2,3-dihydro-1H-pyrrolizin-5-yl] Acetic Acid (Licofelone, ML3000), an Inhibitor of Cyclooxygenase-1 and -2 and 5-Lipoxygenase
2-[6-(4-Chlorophenyl)-2,2-dimethyl-7-phenyl-2,3-dihydro-1H-pyrrolizin-5-yl] acetic acid (licofelone) is a dual inhibitor of both… 
2002
2002
Antithrombotic and platelet function inhibiting effects of ML3000, a new antiinflammatory drug with COX/5-LOX inhibitory activity
Abstract.Design: The studies reported were designed to evaluate the effects of ML3000 on platelet aggregation and platelet… 
2002
2002
First clinical results of licofelone (ml3000), an inhibitor of COX-1, COX-2 and 5-LOX, for the treatment of osteoarthritis
full series of preclinical studies. The GI, renal, hepatic and general tolerability was excellent. In clinical phase II and phase… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)